Call to Action: How Can We Promote the Development of New Pharmacologic Treatments in Chronic Obstructive Pulmonary Disease?

The article discusses the challenges in developing new pharmacologic treatments for Chronic Obstructive Pulmonary Disease (COPD) due to disease heterogeneity, lack of biomarkers, and regulatory constraints. It highlights the need for biomarker discovery, precision medicine approaches, and innovative trial designs to overcome these barriers. The call to action emphasizes investing in research for biomarker identification, incorporating quantitative imaging in trials, and establishing an adaptive platform trial network for rapid evaluation of therapies and endpoints. The article underscores the importance of understanding COPD's diverse phenotypes to advance therapeutic development and improve patient care. [Extracted from the article]